patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_907560 | REC_0002101 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 36 | 10.7 | 65 | female | 1 | 21 | 3.9 | 6 | entrectinib 600 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:57.362915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377581 | REC_0002102 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 6.4 | 72 | female | 1 | 9 | 5.7 | 7 | entrectinib 600 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.363145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658941 | REC_0002103 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5.7 | 75 | female | 2 | 18 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 27.9 | false | MSS | 2026-03-15T05:35:57.363374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753973 | REC_0002104 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 16.7 | 63 | male | 1 | 12 | 5.8 | 2 | osimertinib 80 mg daily | 11.3 | false | MSI-H | 2026-03-15T05:35:57.363611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498355 | REC_0002105 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 7.5 | 59 | male | 1 | 17 | 7.3 | 1 | pembrolizumab 200 mg q3w | 28 | false | MSS | 2026-03-15T05:35:57.363848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140428 | REC_0002106 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 8.5 | 79 | female | 0 | 0 | 6.8 | 5 | alectinib 600 mg BID | 13.4 | false | MSS | 2026-03-15T05:35:57.364123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236983 | REC_0002107 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7 | 67 | male | 1 | 59 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.9 | true | MSS | 2026-03-15T05:35:57.364438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309335 | REC_0002108 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.4 | 72 | female | 1 | 14 | 4 | 6 | entrectinib 600 mg daily | 9.7 | true | MSI-H | 2026-03-15T05:35:57.364679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843973 | REC_0002109 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.9 | 70 | female | 2 | 8 | 7 | 8 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:57.364912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930251 | REC_0002110 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 13.1 | 59 | female | 1 | 13 | 6.2 | 7 | sotorasib 960 mg daily | 11.3 | false | MSI-H | 2026-03-15T05:35:57.365148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611855 | REC_0002111 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 14.1 | 52 | male | 0 | 5 | 3.7 | 6 | alectinib 600 mg BID | 8.5 | false | MSI-H | 2026-03-15T05:35:57.365387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866439 | REC_0002112 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.3 | 61 | male | 1 | 86 | 7.2 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:57.365620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945235 | REC_0002113 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 12 | 66 | female | 1 | 6 | 8.1 | 1 | alectinib 600 mg BID | 13.8 | false | MSI-H | 2026-03-15T05:35:57.365852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475315 | REC_0002114 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 16.4 | 55 | male | 1 | 15 | 5.8 | 1 | alectinib 600 mg BID | 14.3 | false | MSI-H | 2026-03-15T05:35:57.366087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886720 | REC_0002115 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.1 | 58 | male | 0 | 32 | 8 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.9 | false | MSS | 2026-03-15T05:35:57.366320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375242 | REC_0002116 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 23 | 13.7 | 69 | female | 0 | 17 | 6.4 | 0 | pembrolizumab 200 mg q3w | 47.4 | false | MSS | 2026-03-15T05:35:57.366553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652044 | REC_0002117 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.2 | 58 | male | 1 | 22 | 5.3 | 5 | alectinib 600 mg BID | 13.4 | true | MSS | 2026-03-15T05:35:57.366788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144409 | REC_0002118 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.8 | 67 | female | 1 | 24 | 4.2 | 1 | entrectinib 600 mg daily | 23.7 | true | MSI-H | 2026-03-15T05:35:57.367020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510525 | REC_0002119 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 14.5 | 73 | female | 1 | 18 | 4.6 | 2 | entrectinib 600 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:35:57.367252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582982 | REC_0002120 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.5 | 62 | female | 0 | 13 | 3.8 | 5 | entrectinib 600 mg daily | 19.9 | true | MSS | 2026-03-15T05:35:57.367532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881271 | REC_0002121 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 6.4 | 78 | female | 1 | 48 | 7.7 | 2 | pembrolizumab 200 mg q3w | 19.6 | false | MSS | 2026-03-15T05:35:57.367762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829588 | REC_0002122 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 17.9 | 67 | female | 1 | 2 | 7 | 3 | sotorasib 960 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:35:57.367997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970484 | REC_0002123 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 13.2 | 84 | male | 1 | 17 | 5.8 | 9 | osimertinib 80 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:35:57.368371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974778 | REC_0002124 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 12.3 | 74 | female | 2 | 18 | 7 | 1 | osimertinib 80 mg daily | 15.4 | false | MSS | 2026-03-15T05:35:57.368630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577581 | REC_0002125 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 7.2 | 74 | male | 0 | 48 | 4.6 | 1 | pembrolizumab 200 mg q3w | 11.6 | false | MSS | 2026-03-15T05:35:57.368873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262796 | REC_0002126 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 7.8 | 62 | male | 0 | 81 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.7 | true | MSS | 2026-03-15T05:35:57.369114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314285 | REC_0002127 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 9.4 | 60 | male | 1 | 8 | 4.9 | 2 | osimertinib 80 mg daily | 19.9 | true | MSS | 2026-03-15T05:35:57.369354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453962 | REC_0002128 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.9 | 67 | female | 1 | 10 | 4.4 | 7 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:57.369594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795008 | REC_0002129 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 10.7 | 59 | female | 0 | 3 | 4.6 | 6 | entrectinib 600 mg daily | 5.8 | true | MSI-H | 2026-03-15T05:35:57.369833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413022 | REC_0002130 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 26 | 3.7 | 64 | male | 1 | 42 | 6 | 0 | pembrolizumab 200 mg q3w | 47.8 | true | MSS | 2026-03-15T05:35:57.370072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578211 | REC_0002131 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 12.7 | 75 | female | 1 | 10 | 7.7 | 3 | alectinib 600 mg BID | 8.4 | false | MSS | 2026-03-15T05:35:57.370312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250705 | REC_0002132 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.6 | 80 | female | 1 | 11 | 4.4 | 7 | sotorasib 960 mg daily | 6.3 | true | MSI-H | 2026-03-15T05:35:57.370549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411992 | REC_0002133 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 14.3 | 60 | male | 0 | 12 | 6.9 | 7 | sotorasib 960 mg daily | 12 | false | MSI-H | 2026-03-15T05:35:57.370861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680692 | REC_0002134 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 11.3 | 72 | female | 3 | 15 | 3.8 | 5 | osimertinib 80 mg daily | 18.9 | false | MSI-H | 2026-03-15T05:35:57.371101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524402 | REC_0002135 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 18.4 | 65 | female | 1 | 17 | 6.8 | 7 | osimertinib 80 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:57.371338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976683 | REC_0002136 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 8.5 | 71 | female | 2 | 11 | 8.1 | 2 | sotorasib 960 mg daily | 16.5 | false | MSS | 2026-03-15T05:35:57.371571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931816 | REC_0002137 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 18.2 | 48 | male | 0 | 30 | 5.3 | 7 | entrectinib 600 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:57.371809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787465 | REC_0002138 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 34 | 7.3 | 55 | female | 1 | 23 | 4.2 | 7 | pembrolizumab 200 mg q3w | 15.4 | true | MSS | 2026-03-15T05:35:57.372043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994887 | REC_0002139 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 15.8 | 65 | female | 0 | 7 | 6.8 | 5 | sotorasib 960 mg daily | 10 | true | MSS | 2026-03-15T05:35:57.372327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961726 | REC_0002140 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.1 | 70 | female | 2 | 16 | 4.5 | 4 | entrectinib 600 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:57.372562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355256 | REC_0002141 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 9 | 65 | female | 1 | 17 | 4.3 | 6 | entrectinib 600 mg daily | 5.5 | false | MSS | 2026-03-15T05:35:57.372797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232651 | REC_0002142 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 4.1 | 68 | female | 1 | 14 | 6 | 4 | osimertinib 80 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:57.373025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650495 | REC_0002143 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.5 | 51 | female | 0 | 20 | 4.7 | 6 | sotorasib 960 mg daily | 8.4 | false | MSS | 2026-03-15T05:35:57.373260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399456 | REC_0002144 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 8.5 | 60 | male | 1 | 25 | 3.8 | 3 | alectinib 600 mg BID | 15 | true | MSS | 2026-03-15T05:35:57.373493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261884 | REC_0002145 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 16.2 | 66 | male | 1 | 17 | 6 | 6 | sotorasib 960 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:57.373729+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255908 | REC_0002146 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 10.8 | 64 | male | 0 | 13 | 4.4 | 1 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:57.374011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378965 | REC_0002147 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 4.1 | 79 | female | 1 | 20 | 4.8 | 1 | pembrolizumab 200 mg q3w | 29.8 | false | MSS | 2026-03-15T05:35:57.374243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469175 | REC_0002148 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 7.9 | 53 | female | 0 | 10 | 5.7 | 1 | alectinib 600 mg BID | 12 | false | MSS | 2026-03-15T05:35:57.374477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193035 | REC_0002149 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 5.4 | 52 | female | 0 | 16 | 6.3 | 7 | alectinib 600 mg BID | 17.2 | false | MSS | 2026-03-15T05:35:57.374710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120297 | REC_0002150 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15.3 | 66 | male | 0 | 17 | 4.5 | 6 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.374945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919925 | REC_0002151 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.6 | 82 | male | 2 | 8 | 5 | 7 | sotorasib 960 mg daily | 7.2 | true | MSI-H | 2026-03-15T05:35:57.375179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719639 | REC_0002152 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 4.6 | 66 | female | 0 | 15 | 5.2 | 2 | pembrolizumab 200 mg q3w | 24.5 | false | MSS | 2026-03-15T05:35:57.375407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303108 | REC_0002153 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 13.5 | 66 | female | 1 | 19 | 5.4 | 4 | alectinib 600 mg BID | 5.7 | true | MSS | 2026-03-15T05:35:57.375639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323260 | REC_0002154 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 20.4 | 64 | female | 1 | 9 | 4.2 | 0 | osimertinib 80 mg daily | 39 | true | MSI-H | 2026-03-15T05:35:57.375877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504831 | REC_0002155 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.9 | 67 | female | 1 | 23 | 4.3 | 4 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:57.376202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240857 | REC_0002156 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 6.7 | 72 | female | 1 | 20 | 6.5 | 2 | alectinib 600 mg BID | 11.9 | false | MSS | 2026-03-15T05:35:57.376439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229596 | REC_0002157 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 2.9 | 56 | female | 1 | 35 | 5.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:35:57.376674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787799 | REC_0002158 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 8.3 | 66 | female | 1 | 61 | 4.1 | 5 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:57.376904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418481 | REC_0002159 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 10.1 | 66 | female | 1 | 19 | 5.4 | 6 | pembrolizumab 200 mg q3w | 10.1 | true | MSS | 2026-03-15T05:35:57.377190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395169 | REC_0002160 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.3 | 73 | female | 1 | 15 | 5.3 | 2 | sotorasib 960 mg daily | 20.3 | true | MSS | 2026-03-15T05:35:57.377428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151686 | REC_0002161 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.4 | 67 | female | 0 | 49 | 4.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 16.1 | true | MSS | 2026-03-15T05:35:57.377662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764056 | REC_0002162 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 13.9 | 82 | female | 2 | 10 | 5.9 | 6 | alectinib 600 mg BID | 8.2 | false | MSS | 2026-03-15T05:35:57.377895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537205 | REC_0002163 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 16.8 | 62 | male | 0 | 19 | 6 | 6 | sotorasib 960 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:35:57.378131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889182 | REC_0002164 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 8.7 | 81 | male | 2 | 14 | 4.8 | 2 | osimertinib 80 mg daily | 23.1 | false | MSS | 2026-03-15T05:35:57.378364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321628 | REC_0002165 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 7.1 | 76 | female | 2 | 15 | 3.5 | 4 | pembrolizumab 200 mg q3w | 8.9 | false | MSS | 2026-03-15T05:35:57.378592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109913 | REC_0002166 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 9.7 | 72 | female | 2 | 16 | 6.2 | 2 | pembrolizumab 200 mg q3w | 16.7 | true | MSS | 2026-03-15T05:35:57.378832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489575 | REC_0002167 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4 | 65 | male | 0 | 34 | 4.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.6 | false | MSS | 2026-03-15T05:35:57.379088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362017 | REC_0002168 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 9.2 | 75 | female | 1 | 18 | 5.4 | 2 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:57.379343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319323 | REC_0002169 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 17.2 | 59 | female | 1 | 16 | 6.4 | 6 | alectinib 600 mg BID | 12.7 | false | MSI-H | 2026-03-15T05:35:57.379600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549771 | REC_0002170 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 14.1 | 72 | female | 1 | 22 | 5.9 | 1 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:35:57.379844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754358 | REC_0002171 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 10.8 | 57 | female | 0 | 15 | 6.4 | 6 | pembrolizumab 200 mg q3w | 9.8 | true | MSI-H | 2026-03-15T05:35:57.380151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383229 | REC_0002172 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 7.8 | 67 | female | 0 | 16 | 3.9 | 5 | osimertinib 80 mg daily | 6.9 | true | MSS | 2026-03-15T05:35:57.380509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146189 | REC_0002173 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.1 | 81 | female | 2 | 67 | 4.3 | 6 | pembrolizumab 200 mg q3w | 19.5 | true | MSS | 2026-03-15T05:35:57.380758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719004 | REC_0002174 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 23 | 6.6 | 61 | female | 1 | 15 | 5.2 | 0 | pembrolizumab 200 mg q3w | 32.4 | true | MSS | 2026-03-15T05:35:57.381003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553029 | REC_0002175 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.4 | 60 | female | 1 | 0 | 3.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:35:57.381241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263471 | REC_0002176 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 11.3 | 81 | female | 1 | 10 | 5 | 5 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:35:57.381474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_337459 | REC_0002177 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 16.1 | 71 | female | 2 | 13 | 5.7 | 6 | alectinib 600 mg BID | 11.8 | true | MSI-H | 2026-03-15T05:35:57.381706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155443 | REC_0002178 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 13.3 | 63 | male | 0 | 26 | 3.3 | 0 | osimertinib 80 mg daily | 6.5 | false | MSI-H | 2026-03-15T05:35:57.381947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937031 | REC_0002179 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 16.1 | 68 | female | 0 | 10 | 6.8 | 3 | alectinib 600 mg BID | 21.4 | false | MSS | 2026-03-15T05:35:57.382185+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568703 | REC_0002180 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 5.1 | 70 | female | 2 | 73 | 4.1 | 3 | pembrolizumab 200 mg q3w | 13.4 | false | MSS | 2026-03-15T05:35:57.382418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732309 | REC_0002181 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.7 | 73 | female | 1 | 11 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.3 | true | MSS | 2026-03-15T05:35:57.382647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464704 | REC_0002182 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 11.8 | 73 | female | 1 | 10 | 7.3 | 6 | osimertinib 80 mg daily | 12 | false | MSI-H | 2026-03-15T05:35:57.382877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849219 | REC_0002183 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.1 | 59 | female | 1 | 56 | 6.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.1 | true | MSS | 2026-03-15T05:35:57.383111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150557 | REC_0002184 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.3 | 77 | male | 1 | 51 | 6.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.3 | false | MSS | 2026-03-15T05:35:57.383343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327018 | REC_0002185 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 7.2 | 52 | male | 0 | 17 | 3.8 | 5 | osimertinib 80 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:57.383627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401150 | REC_0002186 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 2.8 | 66 | female | 1 | 8 | 6.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.8 | false | MSS | 2026-03-15T05:35:57.383858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423056 | REC_0002187 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 10.8 | 67 | male | 1 | 19 | 5.6 | 5 | sotorasib 960 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:35:57.384133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637777 | REC_0002188 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 8.2 | 74 | male | 0 | 7 | 3.8 | 7 | sotorasib 960 mg daily | 13 | true | MSS | 2026-03-15T05:35:57.384375+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212457 | REC_0002189 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 15.1 | 72 | female | 2 | 9 | 4.3 | 2 | entrectinib 600 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:57.384611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842314 | REC_0002190 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 8 | 58 | female | 0 | 2 | 3.1 | 1 | osimertinib 80 mg daily | 19.8 | false | MSS | 2026-03-15T05:35:57.384843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295984 | REC_0002191 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 9.2 | 77 | female | 3 | 7 | 5.1 | 1 | pembrolizumab 200 mg q3w | 33 | false | MSS | 2026-03-15T05:35:57.385072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139010 | REC_0002192 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.1 | 67 | female | 1 | 19 | 5.5 | 6 | pembrolizumab 200 mg q3w | 10.2 | true | MSS | 2026-03-15T05:35:57.385298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690539 | REC_0002193 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 10.9 | 69 | male | 1 | 19 | 6 | 3 | osimertinib 80 mg daily | 7.5 | false | MSI-H | 2026-03-15T05:35:57.385534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551594 | REC_0002194 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.8 | 82 | female | 1 | 44 | 4.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:57.385760+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101584 | REC_0002195 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 14.3 | 59 | male | 0 | 13 | 7.6 | 2 | osimertinib 80 mg daily | 22.9 | false | MSS | 2026-03-15T05:35:57.385997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694320 | REC_0002196 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.7 | 81 | male | 2 | 8 | 4.6 | 5 | osimertinib 80 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:57.386229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226988 | REC_0002197 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 13.3 | 80 | male | 1 | 10 | 6.6 | 7 | osimertinib 80 mg daily | 5.9 | true | MSS | 2026-03-15T05:35:57.386466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935599 | REC_0002198 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 8.2 | 74 | male | 1 | 18 | 5.7 | 5 | pembrolizumab 200 mg q3w | 16.2 | false | MSS | 2026-03-15T05:35:57.386758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973327 | REC_0002199 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 3.5 | 64 | male | 1 | 75 | 8.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 17 | false | MSS | 2026-03-15T05:35:57.386997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220058 | REC_0002200 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 10 | 55 | male | 1 | 12 | 4.1 | 2 | sotorasib 960 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:57.387233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.